Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout

2018871 citationsJournal Articlebronze Open Access

Authors

William B. White · State University of New York

Kenneth G. Saag · State University of New York

Michael A. Becker · State University of New York

Jeffrey Borer · State University of New York

Philip B. Gorelick · Grand Rapids Community College

Andrew Whelton · State University of New York

Barbara Hunt

Abstract

In patients with gout and major cardiovascular coexisting conditions, febuxostat was noninferior to allopurinol with respect to rates of adverse cardiovascular events. All-cause mortality and cardiovascular mortality were higher with febuxostat than with allopurinol. (Funded by Takeda Development Center Americas; CARES ClinicalTrials.gov number, NCT01101035 .).

Topics & Keywords

Gout, Hyperuricemia, Uric Acid Case Reports on Hematomas Liver Disease and Transplantation

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 378, Issue 13, pp. 1200-1210

DOI: 10.1056/nejmoa1710895

Field-Weighted Citation Impact: 63.96